Both companies plan to develop therapeutics using Celros Biotech's antibody and inflammation control source technology, and AprilBio's anti-Serum Albumin Fab-Associated (SAFA) platform source technology and antibody conjugation technology.
Inflammatory bowel disease is a disease in which abnormal chronic inflammation in the large and small intestine improves and recurs repeatedly. The therapeutic efficacy of current therapeutic antibodies is only 30%, so unmet medical demand is high.
The agreement presents a new concept that the therapeutic effect can be significantly improved by stably double-binding the antibody developed by Celros Biotech with the existing SAFA technology of AprilBio.
"SAFA technology is a platform technology applicable to various drugs and mechanisms, so the effectiveness of SAFA technology can be highly appreciated through the joint development of innovative new drugs for IBD," said Sang-Hoon Cha, CEO at AprilBio.
"We are pleased to cooperate with AprilBio, which has abundant experience and source technology in double-antibody binding. We hope not only to discover new anti-drug candidates effective for the treatment of IBD, but also to continue to cooperate and develop global innovative new drugs with AprilBio in the future," said Yoon-Soo Bae, CEO at Celros Biotech.